OncoMatch/Clinical Trials/NCT06969612
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
Is NCT06969612 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for nsclc (advanced non-small cell lung cancer).
Treatment: Tislelizumab · Pemetrexed · Cisplatin · Carboplatin · Paclitaxel · Albumin Paclitaxel · Golidocitinib — The goal of this clinical trial is to learn if golidocitinib combined with tislelizumab and chemotherapy works in advanced NSCLC with PD-L1≥1%. The main question it aims to answer is: Does the combination of golidocitinib with tislelizumab and chemotherapy can prolong the progression-free survival of patients with advanced NSCLC? Participants will： Take tislelizumab and chemotherapy for 2 cycles; and then take tislelizumab and golidocitinib for 2 cycles; after cycle 5, patients receive tislelizumab and chemotherapy until the patients were intolerant or the disease progressed.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR exon 19 deletion
Histology of lung adenocarcinoma confirmed the presence of EGFR19 deletion or L858R mutation and ALK, ROS-1 fusion gene mutation (non-adenocarcinoma patients are not required to undergo mandatory genetic testing).
Required: EGFR L858R mutation
Histology of lung adenocarcinoma confirmed the presence of EGFR19 deletion or L858R mutation and ALK, ROS-1 fusion gene mutation (non-adenocarcinoma patients are not required to undergo mandatory genetic testing).
Required: ALK fusion gene mutation
Histology of lung adenocarcinoma confirmed the presence of EGFR19 deletion or L858R mutation and ALK, ROS-1 fusion gene mutation (non-adenocarcinoma patients are not required to undergo mandatory genetic testing).
Required: ROS1 fusion gene mutation
Histology of lung adenocarcinoma confirmed the presence of EGFR19 deletion or L858R mutation and ALK, ROS-1 fusion gene mutation (non-adenocarcinoma patients are not required to undergo mandatory genetic testing).
Required: PD-L1 (CD274) PD-L1(22C3) ≥1% (≥1%)
PD-L1(22C3) ≥1%
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic chemotherapy
Cannot have received: biological therapy
Cannot have received: targeted therapy
Cannot have received: immunotherapy
Lab requirements
Blood counts
ANC ≥ 1.5×10^9/L (no growth factor); platelets ≥ 100×10^9/L (no growth factor or transfusion); hemoglobin ≥ 9 g/dL (no transfusion or erythropoietin)
Kidney function
Blood creatinine ≤ 1.5 × ULN, or creatinine clearance rate ≥ 50 mL/min (Cockcroft-Gault or 24h urine)
Liver function
Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN if Gilbert syndrome); ALT and AST ≤ 2.5 × ULN (≤ 5 × ULN with liver metastases)
The bone marrow reserve and organ system functional reserve are sufficient...see full details above
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify